Kaur Jasmeet, Farooqi Humaira, Chandra Kailash, Panda Bibhu Prasad
Microbial and Pharmaceutical Biotechnology Laboratory, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062, India.
Heliyon. 2024 Mar 5;10(5):e27363. doi: 10.1016/j.heliyon.2024.e27363. eCollection 2024 Mar 15.
Mushrooms are traditionally used for various medicinal purposes in traditional oriental medicine. The Japanese and Chinese are familiar with the medicinal macro fungus ( mushroom). This study aims to evaluate the role of chemical compounds from using network pharmacology and studies for management of Obesity. Bioactive compounds in extracts of were identified by GC-MS analysis. Compounds were later screened for their drug-like property by Lipinski's rule. In addition, public databases (SEA, STP, Omim and DisGenet) were searched to identify genes associated with selected molecules and obesity, as well as genes that overlap obesity target genes with genes related to . Additionally, analysis was performed using Enrichr KG to predict the disease targets of . Finally, network was constructed between the overlapping genes and bioactive molecules using Rstudio. Further studies were carried out using 3T3-L1 cell line. The genes related to the selected compounds and obesity were identified and overlapped. The disease targets of was predicted by enrichment analysis and was found to be linked to obesity. Furthermore, the hub gene was found to be fatty acid amide hydrolase, and the key bioactive compound was hexadecanoic acid methyl ester. The cell culture studies confirmed the inhibition of adipogenesis in mushroom extract-treated 3T3-L1 cells and the augmentation of adiponectin. The study suggests that the hub gene fatty acid amide hydrolase might alleviate obesity by inhibiting arachidonoyl ethanolamide signaling, which would enhance the action of fatty acid amide hydrolase and limit appetite in extract.
在传统东方医学中，蘑菇传统上用于各种药用目的。日本人和中国人都熟悉药用大型真菌（蘑菇）。本研究旨在利用网络药理学和实验研究来评估蘑菇化合物在肥胖管理中的作用。通过气相色谱 - 质谱联用（GC - MS）分析鉴定蘑菇提取物中的生物活性化合物。随后根据Lipinski规则筛选化合物的类药性质。此外，搜索公共数据库（SEA、STP、Omim和DisGenet）以鉴定与所选分子和肥胖相关的基因，以及肥胖靶基因与蘑菇相关基因重叠的基因。另外，使用Enrichr KG进行分析以预测蘑菇的疾病靶点。最后，使用Rstudio在重叠基因和生物活性分子之间构建网络。使用3T3 - L1细胞系进行了进一步的实验研究。鉴定并重叠了与所选化合物和肥胖相关的基因。通过富集分析预测了蘑菇的疾病靶点，发现其与肥胖有关。此外，发现枢纽基因是脂肪酸酰胺水解酶，关键生物活性化合物是十六烷酸甲酯。细胞培养研究证实了蘑菇提取物处理的3T3 - L1细胞中脂肪生成的抑制和脂联素的增加。该研究表明，枢纽基因脂肪酸酰胺水解酶可能通过抑制花生四烯酸乙醇酰胺信号传导来减轻肥胖，这将增强脂肪酸酰胺水解酶的作用并限制蘑菇提取物中的食欲。
